Up and Coming

Up and Coming from Altasciences, gvk bioSciences and ObsEva

September 16, 2019

This feature highlights changes in clinical research organizations’ personnel.

AbCellera
AbCellera Biologics Inc. has appointed Andrew Booth chief financial officer. Previously, Booth was vice president of instrumentation, chief financial officer and chief commercial officer at STEMCELL Technologies.

Up and Coming from Aprecia, Bolt and Invicro

September 8, 2019

This feature highlights changes in clinical research organizations’ personnel.

Accent Therapeutics
Accent Therapeutics has appointed Shakti Narayan chief executive officer. Narayan was most recently chief business officer at Tango Therapeutics.

Up and Coming from Amnicell, Eisai and Octernal Theraputics

September 2, 2019

This feature highlights changes in clinical research organizations’ personnel.

Aerie Pharmaceuticals
Luis Vargas has been appointed medical director of medical affairs at Aerie Pharmaceuticals. Vargas previously was the vice president of medical affairs and the medical director at Revision Optics.

Up and Coming from Biolog-id, DrugCendR and Roche

August 26, 2019

This feature highlights changes in clinical research organizations’ personnel.

AKL Research and Development
AKL Research and Development appointed Michael Martin as chief financial officer. Martin has a background in investment banking and was a founding member of Anvil Partners.

Up and Coming from Aperiomics, Curis and OneOme

August 19, 2019

This feature highlights changes in clinical research organizations’ personnel.

AmerisourceBergen
Leslie Donato has been named executive vice president and chief strategy officer at AmerisourceBergen. Donato was previously vice president of strategy at Bayer Pharmaceuticals.

Up and Coming from Astellas, Nimbus and Parexel

August 12, 2019

This feature highlights changes in clinical research organizations’ personnel.

Accelerate Diagnostics
Accelerate Diagnostics has named Jack Phillips chief operating officer. Phillips previously served as president and chief executive officer at Roche Diagnostics.

Up and Coming from GlobalMed, GlaxoSmithKline and Aurinia Pharmaceuticals

July 29, 2019

This feature highlights changes in clinical research organizations’ personnel.

Vertex
Vertex Pharmaceuticals has announced Reshma Kewalramani will assume the role of chief executive officer, effective April 1, 2020, when current CEO Jeffry Leiden transitions to the role of executive chairman of the board. Kewalramani currently serves as chief medical officer, a position she has held since 2017. In addition to CMO, she also serves as executive vice president of global medicines development and medical affairs. Kewalramani will become the first woman to run a large biotechnology firm.

Up and Coming from Anika, Neptune and Skyhawk

July 22, 2019

This feature highlights changes in clinical research organizations’ personnel.

Gilead
Executive shakeup continues at Gilead, where chief scientific officer and R&D head John McHutchison will leave the company next month. Hutchison, a nine-year veteran of the company, stepped into his current position a little more than a year ago. Gilead did not specify a reason for his departure and has not named a successor. Also leaving next month is chief patient officer Gregg Alton, who will serve in an advisory capacity until the end of the year.

Up and Coming from Healthix, Veracyte and Inari Medical

July 15, 2019

This feature highlights changes in clinical research organizations’ personnel.

Healthix
Healthix has announced that Todd Rogow will lead the organization as its new president and chief executive officer. Rogow previously served as senior vice president and chief information officer at the company.